These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 18721806)

  • 1. ErbBs in lung cancer.
    Sharma SV; Settleman J
    Exp Cell Res; 2009 Feb; 315(4):557-71. PubMed ID: 18721806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting ADAMS and ERBBs in lung cancer.
    Hynes NE; Schlange T
    Cancer Cell; 2006 Jul; 10(1):7-11. PubMed ID: 16843261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ErbB family targeting.
    Black JD; Brattain MG; Krishnamurthi SA; Dawson DM; Willson JK
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1451-4. PubMed ID: 14763131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor mutations in small cell lung cancer.
    Tatematsu A; Shimizu J; Murakami Y; Horio Y; Nakamura S; Hida T; Mitsudomi T; Yatabe Y
    Clin Cancer Res; 2008 Oct; 14(19):6092-6. PubMed ID: 18829487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC.
    Hirsch FR
    Oncogene; 2009 Aug; 28 Suppl 1():S1-3. PubMed ID: 19680291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.
    Ramos FJ; Macarulla T; Capdevila J; Elez E; Tabernero J
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S52-7. PubMed ID: 19064407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer.
    Jiang Y; Kimchi ET; Staveley-O'Carroll KF; Cheng H; Ajani JA
    Cancer; 2009 Aug; 115(16):3609-17. PubMed ID: 19526592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of EGFR mutation analysis in non-small cell lung cancer.
    Yamamoto H; Toyooka S; Mitsudomi T
    Lung Cancer; 2009 Mar; 63(3):315-21. PubMed ID: 18760859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy for oesophageal cancer: an overview.
    Syrigos KN; Zalonis A; Kotteas E; Saif MW
    Cancer Metastasis Rev; 2008 Jun; 27(2):273-88. PubMed ID: 18224295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Women and lung cancer: clinical and molecular profiling as a determinate for treatment decisions: a literature review.
    Berardi R; Verdecchia L; Paolo MD; Giampieri R; Scartozzi M; Pierantoni C; Bianconi M; Mazzanti P; Cascinu S
    Crit Rev Oncol Hematol; 2009 Mar; 69(3):223-36. PubMed ID: 18722785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
    Chen FL; Xia W; Spector NL
    Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.
    Toschi L; Jänne PA
    Clin Cancer Res; 2008 Oct; 14(19):5941-6. PubMed ID: 18829470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target-based therapies in breast cancer: current status and future perspectives.
    Normanno N; Morabito A; De Luca A; Piccirillo MC; Gallo M; Maiello MR; Perrone F
    Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
    Modjtahedi H; Essapen S
    Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the EGFR and the PKB pathway in cancer.
    Klein S; Levitzki A
    Curr Opin Cell Biol; 2009 Apr; 21(2):185-93. PubMed ID: 19216065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics in non-small-cell lung cancer chemotherapy.
    Danesi R; Pasqualetti G; Giovannetti E; Crea F; Altavilla G; Del Tacca M; Rosell R
    Adv Drug Deliv Rev; 2009 May; 61(5):408-17. PubMed ID: 19292993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation.
    Cho WC; Chow AS; Au JS
    Eur J Cancer; 2009 Aug; 45(12):2197-206. PubMed ID: 19493678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
    Burris HA
    Oncogene; 2009 Aug; 28 Suppl 1():S4-13. PubMed ID: 19680296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the molecular diagnosis of lung cancer.
    Mao L
    Oncogene; 2002 Oct; 21(45):6960-9. PubMed ID: 12362277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key signaling pathways and targets in lung cancer therapy.
    Choong NW; Salgia R; Vokes EE
    Clin Lung Cancer; 2007 Feb; 8 Suppl 2():S52-60. PubMed ID: 17382025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.